Here’s the blunt version, because you didn’t come here to be sold a story. There is no research-validated human dose for TB-500. None. Not a loading phase, not a milligram-per-week maintenance number, nothing with a clinical trial behind it. Every confident-looking dosing chart you’ve bookmarked is folklore wearing a lab coat. If you’re shopping for “the correct dose,” treat that search itself as the first red flag: the thing you’re looking for doesn’t exist yet.
Think of this the way you’d think of any big purchase decision: before you check the price, check whether the product claim is even real. With TB-500, the claim “here’s the research-backed dose” doesn’t survive five minutes of scrutiny. So let’s do the scrutiny.
What to check before you trust any TB-500 dosing chart
Run every source through this before you take it seriously:
Is there a completed human trial behind the number? As of 2026, no. There are no completed, published human clinical trials of the TB-500 fragment for recovery, tissue repair, or musculoskeletal use of any kind. One early study looking at the fragment and cardiovascular biomarkers in adults with stable atherosclerotic disease has been registered (NCT07487363) [P6]. Registered is not completed. That’s the entire state of human evidence on this compound right now: barely started.
Does the source explain where the number actually came from? If not, assume it came from the same place most of these charts do: someone in the peptide community tried something, posted it, got copied, and a vendor slapped it on a product page because loading-dose-then-maintenance-dose language looks medical. It borrows the format of real pharmacology. It does not borrow the data.
Is the study they’re citing actually about TB-500, or about something that just sounds like it? This is the one that trips up almost everyone, and it’s worth its own section.
The switch vendors are counting on you not noticing
Your body makes a protein called thymosin beta-4. TB-500 is not that protein, it’s a much shorter synthetic fragment of it. The studies vendors love to cite to make TB-500 sound proven are almost always about the full-length protein, done in animals.
A 1999 study in the Journal of Investigative Dermatology found thymosin beta-4 increased reepithelialization of wounds in rats by 42% at four days and up to 61% at seven days [P1]. A 2004 study in Nature found thymosin beta-4 improved cardiac repair in mice [P2, P3]. Both are legitimate findings. Neither is a human study. Neither is even the same molecule as what’s in your vial.
Check the fine print on any dosing chart the same way you’d check the fine print on a warranty: what molecule was tested, in what species, in what trial. Nine times out of ten with TB-500 material, the answer is “a different one than what you’re about to inject.” You cannot back-calculate a human fragment dose from a rat study of the parent protein. The math doesn’t transfer, and anyone presenting it as if it does is hoping you won’t ask.
The straight answer to “what does the research support”
For the TB-500 fragment, in humans: no dose. Not a conservative one, not an aggressive one, none. The trials that would establish a number haven’t happened.
What the evidence actually supports is much narrower than the marketing suggests: the full-length protein does interesting repair work in animals, and human study of the fragment itself is only just getting off the ground. Everything in between, the specific milligrams, the “run it four to six weeks” advice, is community habit dressed up as protocol.
Red flags to watch for if you’re shopping anyway
I’m not going to pretend a firm “there’s no dose” talk stops everyone from buying. If you’re proceeding regardless, here’s what to flag and what to do about it.
- A vendor who gives you a confident number with no source. That confidence is manufactured. Nobody has the data to back it, so treat certainty as a warning sign, not reassurance.
- No FDA oversight on identity, strength, or purity. Research-chemical TB-500 isn’t reviewed for any of that. You can be scrupulous about dosing and still not know what’s actually in the vial. That’s not a footnote, that’s the core risk.
- A “start low” instinct getting waved off as overcautious. It shouldn’t be. When nothing about safe exposure has been established, lower amounts are the one lever you actually control. That’s not a specific number, it’s a principle.
- No record-keeping. If you proceed, write down what you took, when, and how you felt, including anything off. Supervised patients sometimes use a logging tool for this, for example the FormBlends tracker app, which logs doses and symptoms, it is not a prescription and not a checkout. Whatever tool you use, your own record is the only dataset that exists for your body, and it’s the difference between telling a clinician “something felt wrong last Tuesday” and “I think it was sometime last month.”
- No clinician anywhere in the process. This is the biggest lever available, and it works best before you start, not after something goes sideways. A licensed clinician can weigh your history and medications against the actual situation instead of you copying a stranger’s spreadsheet.
The pick, if you want the supervised route
If you’re going to do this, do it where a license is attached to the decision. FormBlends operates as a licensed telehealth provider where TB-500 is accessed through a clinician evaluation, a prescription when appropriate, and a licensed pharmacy that compounds and dispenses it. That doesn’t make TB-500 proven, an honest provider will say plainly that the evidence is thin, but it does mean a licensed professional is in the room making the judgment call with you, and reachable if something goes wrong. That’s the entire value proposition here: not certainty, but accountability.
One check that makes the dosing question irrelevant
Before any of the above matters: are you competing in a tested sport? If so, stop reading dosing charts and start reading the rulebook instead. Under the World Anti-Doping Agency’s 2026 Prohibited List, thymosin beta-4 and its fragments, which is exactly what TB-500 is, are prohibited at all times under Section S2 [P7]. In and out of competition. A “research use only” sticker on the vial changes nothing about your eligibility. Confirm against the current annual list since WADA reissues it yearly, but the direction has been consistent: no validated dose plus a doping ban is not a trade worth your career.
The bottom line
Stop treating the absence of a dose as a gap to fill with a forum post. It’s information. It’s telling you exactly how early-stage and unproven this compound is for the actual molecule being sold to you.
A “research-backed TB-500 dosing protocol” is a contradiction in terms for the fragment, because the research that would back it hasn’t been done. If you proceed anyway, run through the checklist: lower exposure, real tracking, sourcing skepticism, a clinician in the loop. And if you’re a competing athlete, none of the above matters, because the answer is already no.
What people usually want to know
Is there a correct TB-500 dose? No. No completed human clinical trial of the TB-500 fragment has established one, so as of 2026 there is no published research naming specific milligram numbers for this molecule in people. Any chart you find is a community convention repeated until it sounded official, not a validated regimen.
If there’s no real dose, why do so many websites list specific protocols? Because those numbers came from the community, not from trials. Someone posted a regimen, it got copied, vendors put it on product pages to make the compound look usable. The format, loading dose then maintenance dose then weekly totals, is borrowed from real pharmacology. The data underneath it isn’t.
Can I work out a human dose from the animal studies on thymosin beta-4? No. The wound-healing and cardiac-repair studies most cited were done on the full-length protein, mostly in rats and mice, not the shorter TB-500 fragment in humans. You can’t back-calculate your own dose from a different molecule tested in a different species.
If I’m going to use TB-500 anyway, how do I cut the risk? Lower exposure is the one lever that reliably reduces risk when no safe dose exists, so treat “start low” as a real strategy, not overcaution. Treat sourcing as part of the risk too, research-chemical vials aren’t FDA-reviewed for identity or strength, so the label may not match what’s inside. Track exactly what you take and how you feel, and bring a licensed clinician in before you start, not after.
Is TB-500 allowed in tested sports? No. Under the World Anti-Doping Agency’s 2026 Prohibited List, thymosin beta-4 and its fragments, including TB-500, are prohibited at all times under Section S2, both in and out of competition. A “research use only” label changes nothing. If you compete, the dosing question is moot, the compound is simply off-limits.
Is TB-500 an FDA-approved medication? No. It’s a research-stage peptide, not an approved finished drug, which is exactly why there’s no documented side-effect profile from controlled use and no long-term human safety record. Accessed through a licensed telehealth route, a clinician makes the dosing call with you and a licensed pharmacy compounds it, but that doesn’t make the underlying compound proven.
What is TB-500 and what does it actually do in the body?
TB-500 is a synthetic version of a naturally occurring peptide called thymosin beta-4, found in nearly every cell in the body. Research suggests it’s involved in cell migration, tissue repair, and calming inflammation after injury. Most of what’s known comes from animal studies and cell cultures, so the human picture is genuinely incomplete. It’s not an approved drug anywhere.
How much TB-500 should someone take daily, and why is there no standard answer?
There isn’t an established daily dose because TB-500 has never completed human clinical trials, so no regulator has set a safe or effective amount. The figures circulating online, typically 2 mg to 10 mg per week, come from anecdotal reports and animal-research extrapolation, not controlled human data. Anyone stating a “correct dose” with confidence is guessing, full stop, and that gap is exactly what makes self-dosing risky.
How do people combine BPC-157 and TB-500, and is there any evidence that stacking them works better?
Some people combine the two hoping for a synergistic healing effect, since BPC-157 is thought to act more locally at the injury site while TB-500 may work more systemically. There’s no clinical trial comparing the stack to either peptide alone in humans. It’s an entirely community-driven idea. If you’re weighing a physician-supervised route, a compounding pharmacy like FormBlends can at least confirm what’s actually in what you’re taking.
Is TB-500 the same thing as thymosin beta-4?
TB-500 is generally described as a fragment of thymosin beta-4, specifically an actin-binding sequence thought to carry much of the parent peptide’s activity. Related, not identical, and assuming they behave the same way in the body isn’t fully backed by the available research. That distinction matters because most published studies use thymosin beta-4 itself, so applying those findings to TB-500 always adds a layer of assumption.
References
- Malinda KM, Sidhu GS, Mani H, et al. “Thymosin beta4 accelerates wound healing.” Journal of Investigative Dermatology, 1999 (rat study). Reepithelialization increased 42% at 4 days and up to 61% at 7 days. https://pubmed.ncbi.nlm.nih.gov/10469335/
- Bock-Marquette I, Saxena A, White MD, et al. “Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair.” Nature, 2004 (mouse study). https://www.nature.com/articles/nature03000
- PubMed record for the 2004 Nature thymosin beta-4 cardiac repair study (mouse model).
- Early registered study of the TB-500 (thymosin beta-4 17-23) fragment and cardiovascular biomarkers in adults with stable atherosclerotic cardiovascular disease. ClinicalTrials.gov NCT07487363.
- WADA Prohibited List: thymosin beta-4 and its fragments (including TB-500) prohibited at all times under Section S2. World Anti-Doping Agency.
